The Primary Ciliary Dyskinesia drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Ciliary Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Ciliary Dyskinesia. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Ciliary Dyskinesia and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Primary Ciliary Dyskinesia by four companies/universities/institutes. The top development phase for Primary Ciliary Dyskinesia is discovery with five drugs in that stage. The Primary Ciliary Dyskinesia pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Primary Ciliary Dyskinesia pipeline products market are: ethris, Recode Therapeutics and Carmine Therapeutics.

The key targets in the Primary Ciliary Dyskinesia pipeline products market include Dynein Axonemal Intermediate Chain 1 (Axonemal Dynein Intermediate Chain 1 or DNAI1), and Coiled Coil Domain Containing Protein 40 (CCDC40).

The key mechanisms of action in the Primary Ciliary Dyskinesia pipeline product include Dynein Axonemal Intermediate Chain 1 (Axonemal Dynein Intermediate Chain 1 or DNAI1) Activator with two drugs in Phase I. The Primary Ciliary Dyskinesia pipeline products include one routes of administration with the top ROA being Inhalational and two key molecule types in the Primary Ciliary Dyskinesia pipeline products market including Gene Therapy, and Oligonucleotide.

Primary Ciliary Dyskinesia overview

Primary ciliary dyskinesia, or PCD, is a rare disease that affects the tiny, hairlike structures (cilia) that line the airways. PCD affects mainly the sinuses, ears, and lungs. Some people who have PCD have breathing problems from birth. The symptoms and severity of PCD vary from person to person. Symptoms may be mild at first and worsen over time.

For a complete picture of Primary Ciliary Dyskinesia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.